BETHLEHEM, Pa., May 03, 2017 -- B. Braun Medical Inc. will sponsor three educational programs at the Infusion Nurses Society (INS) Spring 2017 Conference that focus on a critical step to peripheral vascular access success, as well as hazardous drug safety. The INS conference is being held May 6-8 at the Minneapolis Convention Center in Minnesota.
In collaboration with Christie Medical Holdings, Inc., B. Braun will present two events directed at improving peripheral vascular access through optimal site assessment.
- An Exhibitor Product Theater CE presentation entitled “Transforming Peripheral Vascular Access” will be held 12:40 to 1:30 p.m. Saturday, May 6, at the rear of the exhibit hall. The presenter is Gregory J. Schears, M.D., Associate Professor of Anesthesiology in Rochester, Minnesota. One CE credit will be offered for this presentation.
- A Simulation Lab event entitled “Targeting Vein Preservation and Optimal Site Choice with Technology” will be held 10:45 a.m. to noon on Sunday, May 7, on the exhibit hall show floor. This program also will be presented by Dr. Schears.
To learn more, visit www.bbrauninsspring.com.
Christie and B. Braun recently announced an alliance, whereby B. Braun will sell the Christie VeinViewer® to hospitals in the United States. VeinViewer technology complements B. Braun’s infusion therapy product line by addressing the first step in peripheral IV therapy success by helping the clinician select the best vein for placing an IV catheter.
“As a leader in infusion therapy, we are committed to facilitating the sharing of knowledge between healthcare professionals,” said Tom Sutton, Vice President of Vascular Access Systems at B. Braun. “By collaborating with Christie and offering these programs at INS, our goal is to bring healthcare experts and practitioners together to discuss current issues and advance clinical PIV knowledge that helps to improve outcomes, as well as the quality, efficiency and safety of healthcare delivery.”
B. Braun also will sponsor a CNE presentation for the INS Daybreak Symposium from 7 to 7:50 a.m. on Tuesday, May 9, in Ballroom A of the Minneapolis Convention Center. “Ready for USP <800>? The Next Chapter in Hazardous Drug Safety” will be presented by Shawn Becker, MS, BSN, Senior Director of Healthcare Quality and Safety, United States Pharmacopeia (USP).
To advance USP <800> awareness and education, B. Braun also will feature the new Readyfor800.com website at the company’s booth (#613). The educational resource provides information that will help prepare clinicians for the new USP <800> guidelines that enhance hazardous drug safety for clinicians and patients. Visitors also will be able to learn about the role of a closed system transfer device (CSTD) and the advantages of B. Braun’s OnGuard® CSTD.
Also at booth #613, B. Braun will showcase the pathway and products that can lead to successful peripheral IV therapy, including the Christie VeinViewer (Christie booth #713), Introcan Safety® family of PIV catheters, STEADYCare™ extension set with the Wedge™ catheter stabilizer, Ster-ASSIST™ sterile peripheral IV catheter insertion kit, CARESITE® luer access device, and InVision-Plus CS® needleless connector.
*VeinViewer is a registered trademark of Christie Medical Holdings, Inc.
Christie is the manufacturer and B. Braun is a distributor of VeinViewer.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]


OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO
Google Secures Pentagon AI Deal for Classified Projects
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 



